Daiwa Securities Group’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.96M | Buy |
22,485
+5,568
| +33% | +$739K | 0.01% | 587 |
|
|
2025
Q4 | $2.4M | Buy |
16,917
+8,179
| +94% | +$1.18M | 0.01% | 616 |
|
|
2025
Q3 | $1.23M | Buy |
8,738
+78
| +0.9% | +$10.6K | ﹤0.01% | 732 |
|
|
2025
Q2 | $1.09M | Sell |
8,660
-2,100
| -20% | -$241K | ﹤0.01% | 736 |
|
|
2025
Q1 | $1.19M | Buy |
10,760
+2,600
| +32% | +$329K | 0.01% | 699 |
|
|
2024
Q4 | $1.11M | Sell |
8,160
-3,638
| -31% | -$450K | 0.01% | 707 |
|
|
2024
Q3 | $1.36M | Buy |
11,798
+2,997
| +34% | +$411K | 0.01% | 672 |
|
|
2024
Q2 | $1.21M | Buy |
8,801
+211
| +2% | +$28.9K | 0.01% | 671 |
|
|
2024
Q1 | $1.19M | Buy |
8,590
+2,109
| +33% | +$288K | 0.01% | 681 |
|
|
2023
Q4 | $854K | Buy |
6,481
+451
| +7% | +$51.9K | 0.01% | 735 |
|
|
2023
Q3 | $678K | Hold |
6,030
| – | – | ﹤0.01% | 770 |
|
|
2023
Q2 | $569K | Buy |
6,030
+264
| +5% | +$25.8K | ﹤0.01% | 794 |
|
|
2023
Q1 | $584K | Buy |
5,766
+200
| +4% | +$20.8K | ﹤0.01% | 779 |
|
|
2022
Q4 | $665K | Sell |
5,566
-3,093
| -36% | -$362K | 0.01% | 745 |
|
|
2022
Q3 | $920K | Sell |
8,659
-90
| -1% | -$9.13K | 0.01% | 665 |
|
|
2022
Q2 | $853K | Sell |
8,749
-1,540
| -15% | -$142K | 0.01% | 695 |
|
|
2022
Q1 | $964K | Sell |
10,289
-41
| -0.4% | -$3.48K | 0.01% | 710 |
|
|
2021
Q4 | $880K | Sell |
10,330
-487
| -5% | -$44.8K | 0.01% | 742 |
|
|
2021
Q3 | $1.04M | Buy |
10,817
+174
| +2% | +$16.4K | 0.01% | 667 |
|
|
2021
Q2 | $1.04M | Sell |
10,643
-226
| -2% | -$21.7K | 0.01% | 627 |
|
|
2021
Q1 | $1.06M | Sell |
10,869
-186
| -2% | -$19.5K | 0.01% | 593 |
|
|
2020
Q4 | $1.06M | Buy |
11,055
+2,288
| +26% | +$221K | 0.01% | 554 |
|
|
2020
Q3 | $843K | Sell |
8,767
-5,392
| -38% | -$624K | 0.01% | 554 |
|
|
2020
Q2 | $866K | Hold |
14,159
| – | – | 0.02% | 409 |
|
|
2020
Q1 | $1.23M | Sell |
14,159
-1,543
| -10% | -$151K | 0.01% | 422 |
|
|
2019
Q4 | $1.69M | Sell |
15,702
-5,807
| -27% | -$608K | 0.01% | 395 |
|
|
2019
Q3 | $1.94M | Sell |
21,509
-2,209
| -9% | -$206K | 0.02% | 353 |
|
|
2019
Q2 | $2M | Sell |
23,718
-3,841
| -14% | -$315K | 0.02% | 335 |
|
|
2019
Q1 | $2.43M | Sell |
27,559
-5,954
| -18% | -$498K | 0.02% | 297 |
|
|
2018
Q4 | $2.39M | Sell |
33,513
-2,683
| -7% | -$257K | 0.02% | 291 |
|
|
2018
Q3 | $4.45M | Sell |
36,196
-13,083
| -27% | -$1.48M | 0.04% | 241 |
|
|
2018
Q2 | $4.84M | Sell |
49,279
-14,108
| -22% | -$1.26M | 0.04% | 237 |
|
|
2018
Q1 | $5.26M | Buy |
63,387
+1,149
| +2% | +$97K | 0.04% | 220 |
|
|
2017
Q4 | $4.83M | Buy |
+62,238
| New | +$4.25M | 0.03% | 246 |
|
Other funds holding NBIX
VPM
VCM
Daiwa Securities Group's NBIX Position: Q1 2026 in Review
Daiwa Securities Group increased its Neurocrine Biosciences (NBIX) stake by 33% in Q1 2026, buying an estimated $739K and bringing the position to 22,485 shares worth $2.96M. The position accounts for 0.01% of the portfolio, ranked #587.
Daiwa Securities Group first reported a position in NBIX in Q4 2017 and has held it in 34 quarters since. The position peaked at $5.26M in Q1 2018. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Daiwa Securities Group held 22,485 shares of Neurocrine Biosciences worth $2.96M as of Q1 2026.
- Daiwa Securities Group bought 5,568 Neurocrine Biosciences shares in Q1 2026, an estimated $739K.
- Neurocrine Biosciences made up 0.01% of Daiwa Securities Group's portfolio in Q1 2026, its #587 holding.
- Daiwa Securities Group first reported a position in Neurocrine Biosciences in Q4 2017 and has held it in 34 quarters since.
- Daiwa Securities Group's Neurocrine Biosciences position peaked at $5.26M in Q1 2018.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.